Furthermore, the authors suggested that a background TET2 mutation alters the transcriptional effects of JAK2 and therefore prevents the upregulation of its proliferative program, potentially resulting in a weaker “MPN-phenotype”, which may on its turn explain the decreased sensitivity towards ruxolitinib. This evidence concerns the gene TET2 and myeloproliferative disorder.